Madrigal Pharmaceuticals (MDGL) Earnings Analysis

Madrigal Pharmaceuticals (MDGL) next reports earnings on 2026-07-30, consensus EPS -2.77348 USD. Last quarter (2026-02-19) it missed with EPS -2.57 USD vs 0.04 USD est (-6525%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -42.00.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MDGL next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate-2.77348 USD
Revenue estimate0.35B

MDGL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-19-2.57 USD0.04 USD-6525%Miss
2025-05-01-3.32 USD-3.62 USD+8.3%Beat
2025-02-26-2.71 USD-4.32 USD+37.3%Beat
2024-10-31-4.92 USD-6.94 USD+29.1%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

MDGL valuation and analyst view

Trailing P/E-42.00
Trailing EPS-10.65833 USD
Price / book28.72
Dividend yield0.00%
Market cap12.51B
Analyst consensusBuy (20 buy / 2 hold / 1 sell)
Avg price target619.5 USD

Related research pages

Frequently asked questions

When is Madrigal Pharmaceuticals (MDGL)'s next earnings date?

Madrigal Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -2.77348 USD and revenue estimate of 0.35B.

Did MDGL beat earnings last quarter?

In its 2026-02-19 report, MDGL posted EPS of -2.57 USD versus a 0.04 USD estimate — a miss of 6525%.

What is MDGL's earnings track record?

Over the last 4 reported quarters with consensus data, MDGL beat estimates 3 times (75%).

What is MDGL's current P/E ratio and EPS?

MDGL trades at a trailing P/E of -42.00 on trailing EPS of -10.658325371544958 USD.

What do analysts rate MDGL?

Analyst consensus is "Buy" across 23 ratings (0 strong buy, 20 buy, 2 hold, 1 sell, 0 strong sell). Average 12-month price target: 619.5 USD.